• Targeting AR and ARv7 in TNBC: EPI-001 as a Molecular Inhibi

  2026-05-20

  This study identifies androgen receptor (AR) and its splice variant ARv7 as markers of poor prognosis and metastasis in triple-negative breast cancer (TNBC). It demonstrates that inhibition of AR/ARv7, particularly with the N-terminal domain inhibitor EPI-001, modulates metastatic and EMT pathways, offering new directions for AR-driven TNBC research.

• Muscle-Derived BDNF Controls Early Postsynaptic NMJ Assembly

  2026-05-19

  This study reveals that spatially localized, muscle-generated BDNF release—regulated by activity and proteolytic processing—directly orchestrates the initial assembly of postsynaptic acetylcholine receptor clusters at neuromuscular junctions. The findings clarify how intracellular trafficking and extracellular conversion of BDNF, including matrix metalloproteinase (MMP) involvement, establish synaptic architecture, opening new avenues for intervention in neuromuscular development.

• Ferroptosis Gene Signature and Atorvastatin in HCC Prognosis

  2026-05-19

  This study establishes a novel prognostic model based on ferroptosis-related genes in hepatocellular carcinoma (HCC) and identifies atorvastatin as a promising inducer of ferroptosis in HCC cells. The findings suggest new avenues for targeted therapy and improved risk stratification in liver cancer research.

• Rapamycin (Sirolimus): Applied mTOR Inhibition for Cancer an

  2026-05-18

  Rapamycin (Sirolimus) is the gold-standard for specific mTOR inhibition, empowering researchers to dissect complex signaling networks in cancer, immunology, and mitochondrial disease. This article delivers actionable workflows, advanced troubleshooting, and practical assay guidance rooted in recent evidence and benchmarked protocols.

• AEBSF.HCl in Necroptosis and Amyloid Research: Protocols & T

  2026-05-18

  AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) powers advanced workflows for dissecting protease-driven cell death and amyloid precursor processing. Here, we translate new mechanistic findings on lysosomal permeabilization into actionable protocols, troubleshooting, and comparative advantages for translational research.

• Phosbind Biotin: Dinuclear Metal Complex for Phosphorylation

  2026-05-17

  Phosbind Biotin leverages dinuclear metal complex phosphate binding for precise, sequence-independent detection of phosphorylated proteins, making it a powerful alternative to traditional phospho-specific antibodies. Its robust Western Blot workflow streamlines signal transduction and plant stress research, notably enabling breakthroughs like phosphorylation-driven drought tolerance mechanisms in Populus trichocarpa.

• Lumiracoxib: Selective COX-2 Inhibitor in Muscle Injury Mode

  2026-05-16

  APExBIO's Lumiracoxib is a robust, highly selective COX-2 inhibitor enabling researchers to dissect the intricacies of inflammation and revascularization in muscle injury models. Its exceptional solubility and temporal control empower advanced COX-2 selective inhibition assays, offering actionable advantages in experimental design and troubleshooting.

• Praeruptorin A: Applied Workflows for Inflammation & Oncolog

  2026-05-15

  Praeruptorin A, a multi-target angular pyranocoumarin compound, unlocks new experimental advantages in anti-inflammatory, ferroptosis, and oncology research. This guide details evidence-backed workflows, optimization tactics, and key troubleshooting steps for maximizing the translational impact of APExBIO’s Praeruptorin A in disease modeling.

• Ginsenoside Rg6 Overcomes Cisplatin Resistance in Ovarian Ca

  2026-05-15

  This study demonstrates that Ginsenoside Rg6 reverses cisplatin resistance in epithelial ovarian cancer (EOC) cells by suppressing protein fucosylation and inducing autophagy via inhibition of the GRB2–ERK1/2–mTOR pathway. These findings provide mechanistic insight into overcoming chemotherapy resistance and suggest new strategies for adjuvant therapy in EOC.

• ML-7 Hydrochloride: Selective MLCK Inhibitor for Cardiovascu

  2026-05-14

  ML-7 hydrochloride is a potent and selective myosin light chain kinase inhibitor widely used in cardiovascular and endothelial dysfunction studies. Its established efficacy in modulating myosin light chain phosphorylation and protecting against ischemia/reperfusion injury is supported by robust quantitative data. This article details the mechanism, benchmarks, and optimized protocols for ML-7 hydrochloride (SKU A3626) from APExBIO.

• JC-1 Enables Advanced Mitochondrial Membrane Potential Assay

  2026-05-14

  JC-1 provides sensitive, ratiometric detection of mitochondrial membrane potential—crucial for apoptosis, bioenergetics, and ferroptosis research. Recent studies highlight its indispensable role in pulmonary fibrosis models, bridging apoptosis detection and the mechanistic study of mitochondrial dysfunction.

• Strategic NOS Inhibition: L-NAME Hydrochloride in Translatio

  2026-05-13

  This thought-leadership article explores the mechanistic, experimental, and translational landscape of L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) as a precision NOS inhibitor. Grounded in evidence and strategic guidance, it advances the discourse on apoptosis and inflammation signaling modulation, vascular tone regulation, and hypertension research, while integrating lessons from cross-domain anti-inflammatory studies.

• DNase I (RNase-free): Precision DNA Removal for RNA Workflow

  2026-05-13

  DNase I (RNase-free) from APExBIO delivers uncompromising DNA removal in RNA extraction, in vitro transcription, and RT-PCR workflows. Its RNase-free purity, cation-tunable specificity, and proven performance empower sensitive molecular biology assays requiring reliable elimination of DNA contamination.

• Affinity-Purified Goat Anti-Mouse IgG (H+L) HRP: Advanced Si

  2026-05-12

  Discover how Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated antibodies enable robust signal amplification in modern immunoassays. Uniquely, this article connects molecular detection to groundbreaking neuroscience tools, providing deeper insights for translational research.

• CD40 and STING Competition Drives IRF4+ B Cell Activation in

  2026-05-12

  This study reveals that competitive binding of CD40 and STING with TRAF2 regulates IRF4-driven B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). The findings elucidate a noncanonical NF-κB pathway mechanism underlying TLS-mediated antitumor immunity, providing new insights for biomarker and therapeutic target development.

16178 records 1/1079 page Next 12345 下5页 Last page